<DOC>
	<DOCNO>NCT00002622</DOCNO>
	<brief_summary>RATIONALE : Talc may relieve malignant pleural effusion . It yet know whether wet talc effective dry talc treat patient malignant pleural effusion . PURPOSE : Randomized phase III trial compare effectiveness wet talc dry talc treat patient malignant pleural effusion .</brief_summary>
	<brief_title>Talc Treating Patients With Malignant Pleural Effusion</brief_title>
	<detailed_description>OBJECTIVES : I . Compare proportion patient successful pleurodesis 30 day follow treatment malignant pleural effusion ( MPE ) talc slurry via chest tube v thoracoscopic talc insufflation . II . Compare cost cost effectiveness treatment MPE . III . Compare time recurrence effusion , duration chest tube drainage sclerosis , extent postinstillation complication toxicity , ability re-expand lung patient randomize 2 treatment . IV . Evaluate quality life pain experience patient treatment . OUTLINE : This randomize study . Patients stratify accord participate institution . Patients randomize one two treatment arm . Arm I : Patients undergo pleurodesis . A chest tube insert , pleural fluid drain 24 hour , lung re-expanded least 90 % full expansion . Within 24-36 hour patient undergo sclerosis talc slurry inject chest tube , clamp . Patients rotate possible direction , hold position 30 minute . After 2 hour chest tube unclamped reattached suction drainage , strictly measure 24-hour total . Following decrease drainage 150 ml/24 hour ( usually second third day postsclerosis ) , chest tube remove . Arm II : Patients receive thoracoscopic insufflation . The chest explore thoracoscopically via single multiple incision use direct videothoracoscopic visualization , lung re-expanded 90 % full expansion . Dry talc pneumatically insufflated chest , complete dispersion throughout hemithorax . Following insufflation , chest drain via chest tube , remove drainage 150 ml/24 hour ( usually day 2 3 follow insufflation ) . Patients remove study disease progression unsuccessful lung re-expansion . Patients follow monthly 6 month relapse survival . PROJECTED ACCRUAL : Approximately 500 patient accrue study 28 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Unilateral malignant pleural effusion require sclerosis ( judged attend surgeon ) At least 3 month since treatment contralateral effusion No chylous effusion PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Able undergo thoracoscopy general local anesthesia ( determined attend surgeon ) Not pregnant Tests observation must complete within 1 week prior randomization ( chest xray within 1 week prior procedure ) PRIOR CONCURRENT THERAPY : No prior intrapleural therapy No systemic therapy within 2 week prior randomization 2 week post pleurodesis Biologic therapy : Not specify Chemotherapy : No new systemic chemotherapy 2 week prior least 2 week pleurodesis Endocrine therapy : No new hormonal therapy 2 week prior least 2 week pleurodesis No concurrent steroid use antiemetic Radiotherapy : Prior radiotherapy allow No radiotherapy entire hemithorax Palliative irradiation symptomatic bone lesion allow affected side field include significant portion pleura Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>malignant pleural effusion</keyword>
</DOC>